Evidence map›Paper›PMID 42872241›Full record

ReviewDrug design, development and therapy2026

Advances in Schaftoside Research: Pharmacological Mechanisms, Pharmacokinetics, and Therapeutic Perspectives.

Mengyue Wang, Shaoze Ren, Li Zhang, Yi Zheng, Junpeng Zhang, Meng Zhao, Shanshan Zhao, Qing Yu, Wenqing Wang, Rutao Bian and 1 more

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mengyue WangThe First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.ORCID 0009-0004-5858-566X
Shaoze RenThe First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.ORCID 0009-0004-4814-8503
Li ZhangDepartment of Pulmonary Medicine II, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.
Yi ZhengDepartment of Cardiovascular Medicine III, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.
Junpeng ZhangDepartment of Cardiovascular Medicine III, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.
Meng ZhaoDepartment of Cardiovascular Medicine III, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.ORCID 0009-0002-7556-4006
Shanshan ZhaoDepartment of Pharmaceutical Preparation, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.
Qing YuThe First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.
Wenqing WangThe First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.
Rutao BianDepartment of Science and Education, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.
Xuegong XuDepartment of Cardiovascular Medicine III, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schaftoside is a flavonoid C-glycoside widely existing in medicinal plants and has been extensively reported due to its pharmacological activities, such as anti-inflammatory, hepatoprotective, antioxidant and neuroprotective activities. These pharmacological activities may be attributed to its effects on apoptosis, autophagy, ferroptosis, pyroptosis, oxidative stress and related signaling pathways. In this review, we summarize recent advances in pharmacological activities and pharmacomechanisms of schaftoside as well as its pharmacokinetic properties, formulation strategies, safety and therapeutic application. The biological effects of schaftoside have been demonstrated in various pathological models by relevant in vitro and in vivo experiments. However, its oral bioavailability is extremely low, which is a big challenge for its further development. Some formulation approaches, especially drug delivery systems, have shown preliminary prospects, but related reports are limited. Based on available toxicological findings, schaftoside is expected to have a relatively safe profile. However, the relationship between schaftoside and chemosensitivity as well as drug resistance needs to be further investigated. In conclusion, schaftoside is a promising bioactive compound; however, its pharmacokinetic properties and available clinical evidence need to be further investigated.

Indexed as

GlycosidesAnimalsAnti-Inflammatory AgentsAntioxidantsHumansAnti-Inflammatory AgentsAntioxidantsC-glycosideGlycosidespharmacokineticsprogrammed cell deathsafetyschaftoside

Identifiers

PMID42872241
PMCPMC13660772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.